Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market Report 2026-2030 | CAGR of 9.10%

Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market Summary
As per Data Bridge Market Research analysis, the Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes Market was estimated at USD 7.29 billion in 2025. The market is expected to grow from USD 7.95 billion in 2026 to USD 11.28 billion in 2030, at a CAGR of 9.10% during the forecast period with driven by the rising demand for precision oncology, increasing genetic screening adoption, advancements in next-generation sequencing technologies, and growing awareness regarding hereditary cancer risk assessment.

Get the full PDF sample copy of the report:
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-brca1-and-brca2-genes-market

The global BRCA1 and BRCA2 genes market is witnessing steady expansion due to increasing prevalence of hereditary breast and ovarian cancers and rising integration of genetic diagnostics into personalized treatment pathways. The market is benefiting from technological progress in genomic sequencing, favorable reimbursement frameworks in developed economies, and growing investments in cancer diagnostics infrastructure. Increasing adoption of companion diagnostics, expansion of direct-to-consumer genetic testing services, and strategic collaborations between biotechnology firms and healthcare providers are further accelerating market growth globally.

Market Size & Forecast
2025 Market Size: USD 7.29 Billion
2026 Projected Market Size: USD 7.95 Billion
2030 Projected Market Size: USD 11.28 Billion
CAGR (2026-2030): 9.10%
Largest Region: North America
Fastest Growing Region: Asia-Pacific

Key Market Report Takeaways

North America accounted for the largest market share of approximately 39%-41% due to advanced genomic testing infrastructure, strong reimbursement coverage, and high awareness of hereditary cancer testing.

Asia-Pacific is projected to register the fastest CAGR during the forecast period owing to expanding healthcare expenditure, increasing cancer screening programs, and rising genomic research investments.

Diagnostic testing kits and sequencing-based solutions represented the leading product segment because of their broad use in hereditary cancer screening and precision oncology workflows.

Next-generation sequencing (NGS) emerged as the dominant technology segment due to its high throughput, cost efficiency, and multi-gene testing capabilities.

Hospitals and diagnostic laboratories remained the leading end-use segment driven by growing adoption of molecular diagnostics and personalized cancer treatment planning.

Increasing prevalence of breast and ovarian cancer cases globally continues to support demand for BRCA gene mutation testing services.

Expansion of precision medicine programs and government-supported genomic initiatives are strengthening long-term market growth potential.

Market Trends & Highlights

North America continues to dominate the global market due to early adoption of precision diagnostics, extensive genetic counseling infrastructure, and strong presence of leading biotechnology companies.

Asia-Pacific is emerging as the fastest-growing region supported by expanding cancer awareness campaigns, favorable healthcare reforms, and rising investments in genomic sequencing capabilities across China, India, and Japan.

Diagnostic screening applications account for the largest revenue contribution as BRCA testing becomes increasingly integrated into preventive oncology and personalized treatment protocols.

Rising prevalence of hereditary cancers, increasing demand for personalized therapeutics, and growing healthcare spending are collectively driving global market expansion.

Advancements in next-generation sequencing, AI-assisted genomic analytics, and liquid biopsy technologies are reshaping the competitive landscape and improving testing accuracy.

Strategic partnerships between pharmaceutical companies, genomic testing firms, and healthcare providers are accelerating innovation, market penetration, and companion diagnostic development globally.

Details about the report and current availability can be viewed :
https://www.databridgemarketresearch.com/reports/global-brca1-and-brca2-genes-market

Market Dynamics

Market Drivers

Rising Adoption of Precision Oncology

The growing shift toward personalized medicine is significantly increasing demand for BRCA1 and BRCA2 gene testing globally. Healthcare providers increasingly utilize genomic profiling to tailor cancer therapies and assess hereditary cancer risks. Precision oncology initiatives across North America and Europe are expanding the integration of BRCA diagnostics into clinical workflows. Increased utilization of PARP inhibitors further strengthens demand for BRCA mutation identification.

Technological Advancements in Genomic Sequencing

Continuous innovation in next-generation sequencing (NGS) and molecular diagnostic platforms has improved testing accuracy, speed, and affordability. Automated sequencing workflows and multiplex testing capabilities are enhancing operational efficiency for laboratories and hospitals. Advanced genomic analytics and AI-enabled interpretation tools are reducing diagnostic turnaround times. These developments are accelerating adoption across developed and emerging healthcare markets.

Increasing Prevalence of Breast and Ovarian Cancer

The growing global burden of breast and ovarian cancer is driving demand for hereditary cancer screening solutions. Rising awareness regarding inherited genetic mutations and early detection benefits has increased patient participation in genetic testing programs. Aging populations and changing lifestyle patterns are contributing to higher cancer incidence rates globally. Governments and healthcare organizations are expanding screening initiatives to improve early diagnosis rates.

Expansion of Government and Healthcare Initiatives

Public health agencies and regulatory bodies are increasingly supporting genomic testing adoption through awareness programs and funding initiatives. Countries across Europe and Asia-Pacific are investing in national genomics programs to improve cancer management outcomes. Favorable reimbursement policies in developed economies are encouraging broader access to BRCA testing services. These initiatives are supporting long-term market penetration and clinical adoption.

Growing Investments in Cancer Diagnostics

Biotechnology companies and healthcare investors are significantly increasing funding toward oncology diagnostics and genomic medicine. Strategic collaborations between pharmaceutical firms and diagnostic providers are accelerating companion diagnostic development. Venture capital investments in precision medicine startups are also driving technological innovation. The expansion of cancer research programs globally continues to create strong commercial opportunities.

Market Restraints

High Cost of Genetic Testing and Sequencing

Advanced BRCA testing procedures and genomic sequencing technologies involve substantial operational and equipment costs. Limited affordability in low- and middle-income economies restricts broader adoption of hereditary cancer diagnostics. High costs associated with genetic counseling and confirmatory testing further increase financial burden on patients. Pricing challenges remain particularly significant across emerging healthcare markets.

Regulatory and Compliance Complexities

Stringent regulatory frameworks governing genetic diagnostics create barriers for market entry and commercialization. Compliance requirements related to data privacy, clinical validation, and diagnostic approvals increase development timelines and operational costs. Differences in regulatory standards across countries complicate international market expansion strategies. These challenges are particularly prominent in Europe and North America.

Limited Awareness in Developing Economies

Despite growing awareness globally, many developing regions still face limited public understanding of hereditary cancer testing benefits. Inadequate genetic counseling infrastructure and shortage of skilled professionals restrict diagnostic adoption. Cultural stigma and lack of routine screening programs further hinder testing uptake. Rural healthcare limitations continue to affect market penetration in several countries.

Data Security and Ethical Concerns

The increasing use of genomic data raises concerns regarding patient privacy, cybersecurity, and ethical handling of genetic information. Unauthorized access to sensitive genomic records may create legal and reputational risks for healthcare providers. Strict compliance with healthcare data protection regulations increases operational complexity. These concerns may slow digital integration and patient participation in certain markets.

Reimbursement Limitations in Emerging Markets

Inconsistent reimbursement frameworks and lack of insurance coverage for genetic testing limit accessibility in several regions. Many healthcare systems still classify BRCA testing as a specialized or premium diagnostic procedure. Out-of-pocket expenses discourage adoption among middle-income patient populations. Reimbursement disparities continue to impact overall market expansion potential.

Market Opportunities

Expansion of Direct-to-Consumer Genetic Testing

The growing popularity of consumer-driven healthcare services presents significant growth opportunities for BRCA testing providers. Digital health platforms and at-home testing kits are improving accessibility and convenience for consumers. Increasing awareness regarding preventive healthcare is driving adoption of personalized genetic risk assessments. This trend is particularly strong in North America and Europe.

Emerging Markets in Asia-Pacific and Latin America

Rapid healthcare infrastructure development across Asia-Pacific and Latin America offers strong untapped growth potential. Governments in China and India are increasing investments in oncology diagnostics and genomic medicine programs. Expanding middle-class populations and rising healthcare spending are improving access to advanced cancer screening solutions. Market participants are increasingly targeting these high-growth regions.

Integration of Artificial Intelligence in Genomics

AI-powered genomic analytics platforms are creating new opportunities for improved mutation detection and clinical decision-making. Advanced bioinformatics solutions can accelerate interpretation of complex genetic data and improve testing efficiency. Integration of AI with precision oncology platforms supports personalized treatment recommendations. These technologies are expected to enhance diagnostic scalability and market competitiveness.

Strategic Collaborations and Companion Diagnostics

Growing partnerships between pharmaceutical companies and diagnostic firms are expanding opportunities in targeted oncology therapeutics. Companion diagnostic development for PARP inhibitors and other personalized cancer therapies is driving demand for BRCA testing. Collaborative research initiatives are accelerating biomarker discovery and commercial innovation. Such alliances strengthen market positioning and global expansion strategies.

Government Genomics Programs and Research Funding

Increasing public investment in genomic medicine and cancer research is creating favorable market conditions. National genome mapping initiatives and precision healthcare strategies are accelerating diagnostic adoption globally. Funding support for clinical trials and cancer screening programs is improving innovation capacity. These initiatives are expected to generate long-term revenue opportunities for market participants.

Market Challenges

Shortage of Skilled Genetic Counselors

The growing demand for BRCA testing has created pressure on the availability of trained genetic counselors and molecular diagnostics specialists. Healthcare systems in emerging economies face limited expertise in hereditary cancer risk interpretation. Workforce shortages may delay testing adoption and clinical decision-making processes. This challenge remains significant in rural and underdeveloped healthcare markets.

Complexity of Genetic Data Interpretation

Accurate interpretation of BRCA mutations requires advanced bioinformatics capabilities and clinical expertise. Variants of uncertain significance (VUS) continue to create diagnostic complexities for healthcare providers. Misinterpretation risks may affect treatment planning and patient outcomes. Laboratories must continuously invest in advanced analytics and validation systems to maintain diagnostic reliability.

Infrastructure Gaps in Developing Regions

Many low-income countries lack advanced laboratory infrastructure required for high-throughput genomic testing. Limited availability of sequencing equipment and diagnostic facilities affects market accessibility. Weak healthcare logistics and inadequate digital integration further constrain operational efficiency. Infrastructure disparities continue to create uneven global market development.

Intense Competitive Pricing Pressure

The increasing number of diagnostic providers and sequencing companies has intensified market competition. Price reductions and commoditization of genetic testing services may impact profit margins for established players. Smaller companies often compete through low-cost offerings, increasing pricing pressure across the industry. Maintaining innovation while ensuring profitability remains a critical challenge.

Supply Chain and Reagent Availability Issues

Global disruptions in laboratory reagent supply chains and semiconductor shortages can affect sequencing equipment production and testing operations. Dependence on specialized raw materials and imported components increases operational vulnerability. Delays in logistics and procurement may impact testing turnaround times. These disruptions became increasingly visible following global healthcare supply chain instability.

Market Segmentation & Analysis

By Product / Component

Diagnostic Testing Kits

Diagnostic testing kits represent the largest revenue-generating segment due to increasing demand for hereditary cancer screening and companion diagnostics. These kits are widely used across hospitals, oncology centers, and diagnostic laboratories for mutation detection. The segment benefits from growing awareness regarding preventive oncology and personalized medicine. The segment is projected to maintain a CAGR above 9% through 2030 due to rising testing volumes globally.

Sequencing Instruments and Platforms

Sequencing platforms are experiencing strong growth due to rapid adoption of next-generation sequencing technologies. These systems enable high-throughput genomic analysis and multi-gene testing capabilities. Demand is particularly high among large research institutes and centralized diagnostic laboratories. Technological innovation and declining sequencing costs continue to support segment expansion.

Bioinformatics and Analytics Solutions

Bioinformatics tools are becoming increasingly important for genomic data interpretation and mutation analysis. The segment is gaining traction due to integration of AI-driven analytics and cloud-based genomic platforms. Healthcare providers are investing in advanced software solutions to improve diagnostic accuracy and workflow efficiency. This segment is expected to witness one of the fastest growth rates during the forecast period.

By Application

Breast Cancer Screening

Breast cancer screening dominates the application segment due to the high prevalence of hereditary breast cancer cases globally. BRCA testing is increasingly integrated into preventive diagnostics and treatment planning protocols. Strong awareness campaigns and government screening initiatives support segment growth. North America and Europe remain the largest contributors to this segment.

Ovarian Cancer Screening

Ovarian cancer testing represents a rapidly growing application area driven by increasing use of BRCA testing for targeted therapy selection. Rising adoption of PARP inhibitors is significantly supporting demand for mutation profiling. The segment is expected to register strong CAGR growth due to expanding oncology treatment personalization globally.

Research and Clinical Studies

Research applications are expanding steadily due to increasing genomic research funding and precision medicine initiatives. Academic institutions and biotechnology companies are investing heavily in cancer biomarker discovery and mutation analysis. Growth in clinical trials related to targeted therapies is further supporting demand.

By End-User

Hospitals and Diagnostic Laboratories

Hospitals and diagnostic laboratories account for the largest market share owing to rising patient testing volumes and advanced molecular diagnostics infrastructure. These facilities increasingly adopt NGS-based workflows for comprehensive genomic profiling. Expansion of oncology departments and precision medicine centers further supports growth. The segment is projected to maintain dominant market share through 2030.

Research Institutes

Research institutes play a significant role in biomarker discovery and hereditary cancer studies. Increasing government and private funding for genomic research is driving segment expansion. Collaboration between universities and biotechnology firms is accelerating innovation in BRCA diagnostics.

Pharmaceutical and Biotechnology Companies

Pharmaceutical companies are increasingly integrating BRCA diagnostics into targeted therapy development and companion diagnostic strategies. Growing investment in oncology drug development is strengthening demand for genomic testing services. The segment is expected to witness strong long-term growth due to precision medicine expansion.

By Technology

Next-Generation Sequencing (NGS)

NGS remains the dominant technology segment due to its high accuracy, scalability, and cost-effectiveness. The technology supports simultaneous analysis of multiple genes, improving testing efficiency and clinical utility. Increasing adoption of NGS across hospitals and research centers continues to drive segment leadership.

Polymerase Chain Reaction (PCR)

PCR-based testing remains widely utilized for targeted mutation detection and confirmatory testing procedures. The technology offers rapid turnaround times and lower operational costs. PCR maintains relevance particularly in small and mid-sized diagnostic laboratories.

Microarray Technology

Microarray-based testing is used for large-scale genomic analysis and mutation profiling. Although growth is comparatively slower than NGS, the technology continues to support specialized research applications. Demand remains stable in academic and clinical research environments.

Regional Analysis

By geography, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America dominates the global BRCA1 and BRCA2 genes market, accounting for approximately 39%-41% of total market revenue. The region benefits from advanced healthcare infrastructure, widespread adoption of genomic diagnostics, and strong reimbursement frameworks. The United States remains the leading contributor due to extensive precision oncology programs and presence of major biotechnology companies. High awareness regarding hereditary cancer screening and strong research funding further support regional leadership. The region also benefits from established supply chains and advanced laboratory ecosystems.

Europe

Europe represents a mature and steadily growing market supported by strong regulatory standards and increasing investments in genomic medicine. Countries such as Germany, the U.K., and France are leading contributors due to robust healthcare systems and growing cancer screening programs. Rising focus on precision oncology and collaborative cancer research initiatives continue to drive demand. Regulatory support for personalized medicine and strong academic-industry partnerships strengthen the regional market outlook.

Asia Pacific

Asia Pacific is projected to register the fastest growth during the forecast period due to rapid healthcare modernization and increasing adoption of genomic technologies. China, India, and Japan are investing significantly in oncology diagnostics and genomics research infrastructure. Rising cancer prevalence, expanding healthcare access, and supportive government initiatives are accelerating market expansion. Increasing private-sector investments and growing biotechnology ecosystems further enhance regional growth opportunities.

Latin America

Latin America represents an emerging market with gradual growth driven by improving healthcare infrastructure and increasing awareness of cancer diagnostics. Brazil and Mexico are the major contributors due to expanding healthcare spending and growing diagnostic laboratory networks. However, limited reimbursement coverage and economic instability continue to restrict broader adoption. Gradual integration of advanced sequencing technologies is expected to support future market development.

Middle East & Africa

The Middle East & Africa market is witnessing steady but comparatively slower growth due to infrastructure limitations and restricted access to advanced genomic diagnostics. Government healthcare modernization initiatives and increasing private-sector investments are improving market conditions. Countries in the Gulf region are investing in precision medicine programs and advanced oncology care centers. However, limited skilled workforce availability and uneven healthcare access remain key challenges.

Key Insights
Largest Region: North America
Fastest Growing Region: Asia-Pacific
Mature Markets: North America and Europe
High-Growth Markets: Asia-Pacific

Emerging Markets: Latin America and Middle East & Africa
Regional performance differences are influenced by healthcare spending, genomic infrastructure, technology adoption, reimbursement systems, and local manufacturing ecosystems.

North America and Europe benefit from strong supply chain integration and advanced research ecosystems, while Asia-Pacific gains momentum from industrialization and rising healthcare investments.

Trade policies, cross-border genomic collaborations, and geopolitical factors continue to influence regional supply chain stability and investment trends.

Competitive Landscape

Market Structure Overview

The global BRCA1 and BRCA2 genes market is moderately consolidated, with competition driven by multinational biotechnology firms, specialized diagnostics companies, and emerging genomic startups. Leading companies maintain strong market positions through extensive product portfolios, advanced sequencing technologies, and global distribution networks. Innovation intensity remains high due to rapid advancements in precision oncology and molecular diagnostics. Competitive landscape analysis helps stakeholders evaluate technological capabilities, strategic positioning, and long-term growth potential of key market participants.

Key Industry Players

Major companies operating in the market focus on advanced genomic sequencing platforms, companion diagnostics, and hereditary cancer testing solutions. Industry leaders emphasize technological innovation, portfolio diversification, and strategic collaborations to strengthen competitive positioning. Global players maintain strong geographic reach across North America, Europe, and Asia-Pacific. Companies are increasingly investing in AI-enabled genomics, cloud-based analytics, and personalized oncology solutions.

List of Key Industry Players

Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN N.V.
Myriad Genetics, Inc.
Abbott Laboratories
Agilent Technologies, Inc.
BGI Genomics Co., Ltd.
Eurofins Scientific
Invitae Corporation
Competitive Strategies

Companies are actively pursuing product innovation and next-generation sequencing advancements to enhance diagnostic accuracy and operational efficiency. Strategic collaborations between pharmaceutical and diagnostics companies are accelerating companion diagnostic development for targeted therapies. Mergers and acquisitions are enabling firms to strengthen technology portfolios and expand geographic presence. Leading participants are also investing in digital genomics platforms and bioinformatics solutions to improve customer value proposition and achieve competitive differentiation.

Emerging Players & Market Dynamics

Emerging startups and niche genomic testing companies are intensifying market competition through specialized and cost-effective testing solutions. These firms increasingly focus on AI-driven analytics, direct-to-consumer testing, and cloud-based genomic services. Rising venture capital investments and healthcare innovation funding are supporting new market entrants. Digital transformation and precision medicine trends continue to reshape competitive dynamics and accelerate technological disruption across the industry.

Latest Developments

January 2025 - Illumina, Inc.: Expanded its oncology sequencing portfolio with enhanced multi-cancer genomic testing capabilities, strengthening its competitive position in precision oncology diagnostics and increasing adoption of advanced BRCA testing workflows.
October 2024 - QIAGEN N.V.: Introduced upgraded companion diagnostic solutions integrated with automated genomic analysis platforms, improving testing efficiency and supporting personalized oncology treatment strategies globally.
June 2024 - Thermo Fisher Scientific Inc.: Announced expansion of its genomic sequencing manufacturing capacity in Asia-Pacific to address rising regional demand for hereditary cancer testing and precision medicine applications.
March 2024 - Roche Diagnostics: Strengthened partnerships with oncology research institutes to accelerate development of AI-enabled cancer diagnostics and companion testing solutions for targeted therapies.
November 2023 - Myriad Genetics, Inc.: Expanded hereditary cancer screening services through enhanced digital genetic counseling platforms, improving patient accessibility and supporting growth in preventive oncology diagnostics.
August 2023 - BGI Genomics: Increased investments in high-throughput sequencing infrastructure across China and Southeast Asia to strengthen regional market presence and support precision medicine initiatives.
April 2023 - Eurofins Scientific: Expanded molecular diagnostics laboratory operations in Europe to increase genomic testing capabilities and improve turnaround times for oncology-related diagnostics.
February 2023 - Abbott Laboratories: Enhanced molecular diagnostics portfolio through strategic investments in genomic testing technologies aimed at strengthening oncology diagnostics and personalized healthcare solutions globally.

Check out more related studies published by Data Bridge Market Research:

https://www.databridgemarketresearch.com/reports/global-wearable-devices-market

https://www.databridgemarketresearch.com/reports/thailand-clinical-laboratory-services-market

https://www.databridgemarketresearch.com/reports/global-electronic-data-capture-edc-systems-market

https://www.databridgemarketresearch.com/reports/global-vascular-surgery-and-endovascular-procedures-market

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com

Data Bridge Market Research is dedicated to deliver market intelligence with highest quality and accuracy. Through meticulous analysis and research, we strive to provide our clients with reliable and precise insights into various industries and markets.

This release was published on openPR.